In response to the 2024–2025 global dengue emergency, the World Health Organization (WHO) activated its Expert Review Panel for Diagnostics (ERPD) to guide the selection and use of appropriate diagnostic tools for dengue. This initiative was coordinated by the Public Health Laboratory Strengthening unit of the WHO Health Emergencies Programme and the Global Neglected Tropical Diseases Programme in collaboration with WHO's Prequalification Programme.
The ERPD provides an expert-driven mechanism to evaluate the potential risks and benefits of in vitro diagnostic (IVD) medical devices that are not currently covered by WHO's prequalification process or other stringent regulatory assessment. Comprising an independent advisory group of technical experts, the ERPD assesses whether candidate diagnostics meet defined quality and performance criteria and classifies their risk to support evidence-based procurement decisions. Recognizing critical gaps in the availability of IVDs – particularly for epidemic-prone neglected tropical diseases – WHO supports the procurement of diagnostic products and laboratory items essential for managing a wide range of communicable and noncommunicable diseases.
Following a thorough review process, seven diagnostic products for dengue have been listed. These recommendations are valid for one year and are intended to facilitate timely and informed procurement decisions in the global health response to the dengue emergency.
